CDSCO panel weighing risks and benefits of Covid drug Molnupiravir

The drug is not authorised for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth

Opinion People meeting
Picture: Pixabay

Last Updated on December 27, 2021 by The Health Master

Antiviral Covid-19 pills People in the know said that Molnupiravir, which received emergency use authorisation (EUA) from the USFDA on Thursday, is likely to be narrowly endorsed in India.

The Subject Expert Committee (SEC) under the drug regulator of India has asked manufacturers in India to specify the category of Covid patients that are likely to receive the greatest benefit of the treatment indicated.

The committee in its last meeting earlier this month noted safety issues including embryo-foetal toxicities, bone marrow toxicity, mutagenicity, etc were reported either in-vitro or in some species of animals.

It also observed that there was a reduction in efficacy when compared with Merck’s data of the earlier interim analysis with that of the full population.

In the light of this, the SEC asked the companies about “details of risk mitigation plan and specific category of covid patients that are likely to receive the benefit of the treatment, for which the drug may be indicated,” said the minutes of the meeting.

The USFDA issued an EUA for the treatment of mild-to-moderate coronavirus disease in adults who are at high risk for progression to severe COVID-19, including hospitalisation or death.

The USFDA also said the drug should be given to patients for whom alternative COVID-19 treatment options authorised by the USFDA are not accessible or clinically appropriate.

The drug is not authorised for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth

Molnupiravir developed by MSD and Ridgeback Biotherapeutics works by introducing errors into the SARS-CoV-2 virus’ genetic code, which prevents the virus from further replicating. Molnupiravir is administered as four 200 milligram capsules taken orally every 12 hours for five days, for a total of 40 capsules. Molnupiravir is not authorised for use for longer than five consecutive days.

The SEC is reviewing the applications of Indian drugmakers such as Dr. Reddy’s, Hetero Labs, Natco Pharma, Aurobindo Pharma, Optimus Pharma, Strides Pharma, MSN Pharma, and BDR Pharmaceuticals.

It earlier reported that the panel sought more data from the companies. “The companies have submitted the data, and the SEC is expected to meet soon to review it, the person added.

5 reasons why e-Rx (electronic prescription) is better than paper Rx

At-home COVID-19 rapid test gets ok from USFDA: Roche

Remdesivir drug should only be used in patients with ‘moderate to…

Schedule for 19 FDCs permitted pre-1988 to give online presentation

DCGI seeks more data from Serum Institute for Covovax Vaccine

Doctor couple booked for using restricted drug at hospital

IPC adds 15 new impurities Reference Substances and 11 IP Reference…

Drug alert: 22 out of 1102 samples declared as NSQ in…

Haryana is the best state for setting up Pharma Industries: HM

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner